

Instance: composition-en-d4694a613bca8c68b89018731c6d00bf
InstanceOf: CompositionUvEpi
Title: "Composition for brinavess Package Leaflet"
Description:  "Composition for brinavess Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - brinavess"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet 
1. What BRINAVESS is and what it is used for 
2. What you need to know before you use BRINAVESS 
3. How to use BRINAVESS<br />
4. Possible side effects 
5. How to store BRINAVESS 
6. Contents of the pack and other information </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What brinavess is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What brinavess is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>BRINAVESS contains the active substance vernakalant hydrochloride. BRINAVESS works by 
changing your irregular or fast heart beat to a normal heart beat.  </p>
<p>In adults it is used if you have a fast, irregular heart beat called atrial fibrillation which has started 
recently, less than or equivalent to 7 days, for non-surgery patients and less than or equivalent 
to 3 days for post-cardiac surgery patients.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take brinavess"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take brinavess"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use BRINAVESS 
* if you are allergic to vernakalant hydrochloride or any of the other ingredients of this medicine 
(listed in section 6) 
* if you have had new or worsening chest pain (angina) diagnosed by your doctor as an acute 
coronary syndrome in the last 30 days or you have had a heart attack in the last 30 days<br />
* if you have a very narrow heart valve, systolic blood pressure less than 100 mm Hg or advanced 
heart failure with symptoms at minimal exertion or at rest 
* if you have an abnormally slow heart rate or skipped heart beats and do not have a pacemaker, 
or you have conduction disturbance called QT prolongation - which can be seen on an ECG by 
your doctor 
* if you take certain other intravenous medicines (antiarrhythmics Class I and III) used to 
normalise an abnormal heart rhythm, 4 hours before BRINAVESS is to be used </p>
<p>You must not use BRINAVESS if any of the above apply to you. If you are not sure, talk to your 
doctor before you use this medicine. </p>
<p>Warnings and precautions 
Talk to your doctor before using BRINAVESS if you have: 
* heart failure<br />
* certain heart diseases involving the heart muscle, lining that surrounds the heart and a severe 
narrowing of the heart valves 
* a disease of the heart valves 
* liver problems 
* you are taking other rhythm control medicines </p>
<p>If you have very low blood pressure or slow heart rate or certain changes in your ECG while using this 
medicine, your doctor will stop your treatment. 
Your doctor will consider if you need additional rhythm control medicine 4 hours after using 
BRINAVESS. 
BRINAVESS may not work in treating some other kinds of abnormal heart rhythms, however your 
doctor will be familiar with these. 
Tell your doctor if you have a pacemaker. </p>
<p>If any of the above apply to you (or you are not sure), talk to your doctor. Detailed information on 
warnings and precautions relating to side effects that could occur are presented in section 4. Blood tests 
Before giving you this medicine, your doctor will decide whether to test your blood to see how well it 
clots and also to see your potassium level.  </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents less than 18 years of age because there is no 
experience on its use in this population.  </p>
<p>Other medicines and BRINAVESS 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Do not use BRINAVESS if you take certain other intravenous medicines (antiarrhythmics Class I and 
III) used to normalise an abnormal heart rhythm, 4 hours before BRINAVESS is to be used. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before using this medicine. </p>
<p>It is preferable to avoid the use of BRINAVESS during pregnancy. 
It is not known whether BRINAVESS passes into the breast milk. </p>
<p>Driving and using machines 
It should be taken into account that some people may get dizzy after receiving BRINAVESS, usually 
within the first 2 hours (see section  Possible side effects ). If you get dizzy, you should avoid driving 
or operating machinery after receiving BRINAVESS. </p>
<p>BRINAVESS contains sodium 
This medicine contains 32 mg sodium (main component of cooking/table salt) in each 200 mg vial. 
This is equivalent to 1.6 % of the recommended maximum daily dietary intake of sodium for an adult. 
This medicine contains 80 mg of sodium (main component of cooking/table salt) in each vial of 
500 mg. This is equivalent to 4 % of the recommended maximum daily dietary intake of sodium for an 
adult. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take brinavess"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take brinavess"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The amount of BRINAVESS you may be given will depend on your weight. The recommended initial 
dose is 3 mg/kg, with a maximum calculated dose based upon 113 kg. If you weigh more than 113 kg, 
you will receive a fixed dose of 339 mg. While you are being given BRINAVESS, your breathing, 
heart beat, blood pressure and the electrical activity of your heart will be checked.  </p>
<p>If your heart beat has not returned to normal 15 minutes after the end of your first dose, you may be 
given a second dose. This will be a slightly lower dose of 2 mg/kg, with a maximum calculated dose 
based upon 113 kg. If you weigh more than 113 kg, you will receive a fixed dose of 226 mg. Total 
doses of greater than 5 mg/kg should not be administered within 24 hours. </p>
<p>BRINAVESS will be given to you by a health care professional. BRINAVESS will be diluted before 
being given to you. Information on how to prepare the solution is available at the end of this leaflet. </p>
<p>It will be given to you into your vein over 10 minutes. </p>
<p>If you are given more BRINAVESS than you should 
If you think that you may have been given too much BRINAVESS, tell your doctor straight away. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Your doctor may decide to stop the infusion if he observes any of the following abnormal changes of: 
* your heart beat (such as a very fast (uncommon) or very slow heart beat (common), a missed 
beat (uncommon), or a short pause in the normal activity of your heart (uncommon)) 
* your blood pressure (such as a very low blood pressure causing a serious heart condition) 
(uncommon) 
* the electrical activity of your heart (uncommon) </p>
<p>Other side effects: </p>
<p>Very common (may affect more than 1 in 10 people)<br />
<em> taste disturbances<br />
</em> sneezing </p>
<p>Common (may affect up to 1 in 10 people) 
* fast heart beat 
* pain or numbness at the infusion site, numbness, decreased skin sensation, or tingling feelings<br />
<em> nausea and vomiting<br />
</em> feeling hot 
* low blood pressure, slow heart beat, feeling dizzy 
* coughing, sore nose 
* excessive sweating, itching 
* numbness or tingling that occurs in the mucosa or tissues of the oral cavity </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* certain kinds of heart beat problems, (such as an awareness of your heart beating (palpitations) 
or an extra heart beat) 
* decreased feeling or sensitivity<br />
<em> eye irritation, watery eyes or changes in your vision 
* a change in your sense of smell 
* pain in your fingers and toes, a burning feeling 
* cold sweats, hot flush 
* urgency to have a bowel movement, diarrhoea 
* shortness of breath or a tightness in the chest 
* choking sensation 
* pain in your mouth or throat 
* irritation, itching at the infusion site<br />
</em> high blood pressure 
* feeling light-headed or fainting, generally feeling unwell, feeling drowsy or sleepy 
* runny nose, sore throat 
* stuffy nose 
* dry mouth 
* pale skin 
* generalised itching 
* fatigue 
* decreased feeling or sensitivity of the mouth </p>
<p>These effects, seen within 24 hours of being given BRINAVESS, should pass quickly, however, if 
they do not you should consult your doctor. </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store brinavess"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store brinavess"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>BRINAVESS must be diluted before it is used. The diluted sterile concentrate is chemically and 
physically stable for 12 hours at or below 25  C. </p>
<p>From a microbiological point of view, the medicine should be used immediately. If not used 
immediately, in-use storage times and conditions prior to use are the responsibility of the user and 
would normally not be longer than 24 hours at 2  C to 8  C, unless dilution has taken place in 
controlled and validated aseptic conditions. </p>
<p>Do not use this medicine if you notice particulate matter or discolouration. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What BRINAVESS contains 
* The active substance is vernakalant hydrochloride. Each ml of concentrate contains 20 mg 
vernakalant hydrochloride equivalent to 18.1 mg vernakalant. 
Each vial of 200 mg vernakalant hydrochloride is equivalent to 181 mg vernakalant.<br />
Each vial of 500 mg of vernakalant hydrochloride is equivalent to 452.5 mg of vernakalant. 
* The other ingredients are citric acid, sodium chloride, sodium hydroxide (E524) and water for 
injections (see section 2   BRINAVESS contains sodium ). </p>
<p>What BRINAVESS looks like and contents of the pack 
BRINAVESS is a concentrate for solution for infusion (sterile concentrate) which is clear and 
colourless to pale yellow. 
BRINAVESS is available in pack of 1 vial containing 200 mg or 500 mg of vernakalant 
hydrochloride.  </p>
<p>Marketing Authorisation Holder: 
Correvio<br />
15 rue du Bicentenaire 
92800 Puteaux 
France<br />
Manufacturer: 
Geodis CL Netherlands B.V. 
Columbusweg 5928 LC Venlo 
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. 
Belgi /Belgique/Belgien 
Correvio 
T l/Tel: +32 (0)800 78 medicalinformation@advanzpharma.com </p>
<p>Lietuva 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Correvio 
 .: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Luxembourg/Luxemburg 
Correvio 
T l/Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>esk  republika 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Magyarorsz g 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com  </p>
<p>Danmark 
Correvio 
Tlf: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Malta 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Deutschland 
Correvio 
Tel: +49 (0)800 180 20 medicalinformation@advanzpharma.com </p>
<p>Nederland 
Correvio 
Tel: +31 (0)800 022 93 medicalinformation@advanzpharma.com </p>
<p>Eesti 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Norge 
Correvio 
Tlf: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Correvio 
 : +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>sterreich 
Correvio 
Tel: +43 (0)800 298 medicalinformation@advanzpharma.com </p>
<p>Espa a 
Advanz Pharma Spain S.L.U<br />
Tel: +34 900 834 medicalinformation@advanzpharma.com </p>
<p>Polska 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>France 
Correvio 
T l: +33 1 77 68 89 medicalinformation@advanzpharma.com </p>
<p>Portugal 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Hrvatska 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Ireland 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Rom nia 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Slovenija 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>sland 
Correvio 
S mi: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Slovensk  republika 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Italia 
Correvio 
Tel: +39 800 909 medicalinformation@advanzpharma.com </p>
<p>Suomi/Finland 
Correvio 
Puh/Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Correvio 
 : +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>Sverige 
Correvio 
Tel: +46 (0)20 088 02 medicalinformation@advanzpharma.com </p>
<p>Latvija 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>United Kingdom (Northern Ireland) 
Correvio 
Tel: +44 (0) 208 588 9medicalinformation@advanzpharma.com </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information<br />
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

